Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study
Conclusion: Immune checkpoint inhibitors administration triggers a range of musculoskeletal adverse events, warranting the optimization of their management during clinical practice.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Arthritis | Brain | CIDP | Databases & Libraries | Drugs & Pharmacology | Guillain-Barr Syndrome | Myasthenia Gravis | Neurology | Orthopaedics | Rhabdomyolysis | Rheumatology | Statistics | Study | Toxicology | Yervoy